Regenerx Biopharmaceuticals Inc (OTCMKTS:RGRX) major shareholder Spa Essetifin bought 17,933,673 shares of the company’s stock in a transaction dated Tuesday, March 13th. The stock was purchased at an average price of $0.23 per share, with a total value of $4,124,744.79. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.
Shares of OTCMKTS:RGRX remained flat at $$0.22 during midday trading on Friday. 15,743 shares of the stock traded hands, compared to its average volume of 62,574. The company has a quick ratio of 0.30, a current ratio of 0.30 and a debt-to-equity ratio of -0.10. Regenerx Biopharmaceuticals Inc has a one year low of $0.14 and a one year high of $0.38.
COPYRIGHT VIOLATION WARNING: This article was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another site, it was stolen and reposted in violation of U.S. and international trademark and copyright legislation. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/08/regenerx-biopharmaceuticals-inc-rgrx-major-shareholder-acquires-4124744-79-in-stock.html.
About Regenerx Biopharmaceuticals
RegeneRx Biopharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development of a therapeutic peptide, Thymosin beta 4 (Tb4), for tissue and organ protection, repair and regeneration. The Company’s segment is the development and marketing of product candidates based on Tb4, an amino acid peptide.
Receive News & Ratings for Regenerx Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenerx Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.